These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28132761)

  • 41. Angiographic patterns of restenosis with 2nd generation drug-eluting stent: comparative analysis from a 10-year single-center experience .
    Lee S; Yoon CH; Oh IY; Suh JW; Cho YS; Cho GY; Chae IH; Choi DJ; Youn TJ
    Int Heart J; 2015; 56(1):6-12. PubMed ID: 25503656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravascular Ultrasound Predictors of Major Adverse Cardiovascular Events After Implantation of Everolimus-eluting Stents for Long Coronary Lesions.
    Lee SY; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):88-95. PubMed ID: 27789170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.
    Liistro F; Porto I; Angioli P; Grotti S; Ducci K; Falsini G; Bolognese L
    Am Heart J; 2013 Nov; 166(5):920-6. PubMed ID: 24176449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention.
    Allahwala UK; Cockburn JA; Shaw E; Figtree GA; Hansen PS; Bhindi R
    EuroIntervention; 2015 Feb; 10(10):1154-9. PubMed ID: 24647105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of neointimal coverage and extra-stent lumen between sirolimus and everolimus-eluting stent using optical coherence tomography.
    Oda T; Okamura T; Yamada J; Miyagi N; Uehara H; Nao T; Tateishi H; Maeda T; Nakamura T; Shiraishi K; Nakashima T; Nishimura S; Miura T; Matsuzaki M; Yano M
    Heart Vessels; 2016 Apr; 31(4):449-56. PubMed ID: 25614415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
    Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
    Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation.
    Tada T; Kadota K; Hosogi S; Miyake K; Ohya M; Amano H; Izawa Y; Kanazawa T; Kubo S; Ichinohe T; Hyoudou Y; Hayakawa Y; Sabbah MM; Otsuru S; Hasegawa D; Habara S; Tanaka H; Fuku Y; Katoh H; Goto T; Mitsudo K
    Eur Heart J Cardiovasc Imaging; 2015 Oct; 16(10):1101-11. PubMed ID: 25762559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.
    Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G
    BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
    Diletti R; Farooq V; Girasis C; Bourantas C; Onuma Y; Heo JH; Gogas BD; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn RJ; Smits P; Koolen J; Meredith I; Li X; Miquel-Hebert K; Veldhof S; Garcia-Garcia HM; Ormiston JA; Serruys PW
    Heart; 2013 Jan; 99(2):98-105. PubMed ID: 23118346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents.
    Song L; Mintz GS; Yin D; Yamamoto MH; Chin CY; Matsumura M; Fall K; Kirtane AJ; Parikh MA; Moses JW; Ali ZA; Shlofmitz RA; Maehara A
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1115-1124. PubMed ID: 28281026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Managing distorted ABSORB Scaffold in left main during anomalous LMCA stenting.
    Rath PC; Reddy KC; Agarwala MK; Purohit BV
    Indian Heart J; 2015; 67(3):268-70. PubMed ID: 26138187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Strut Coverage at 6 Months by Optical Coherence Tomography With Everolimus-Eluting Stenting of Bare-Metal Stent Restenosis Versus Stenosis of Nonstented Atherosclerotic Narrowing (from the DESERT Study).
    Picchi A; Musumeci G; Calabria P; Cresti A; Rescigno R; Aruffo A; Prati F; Limbruno U
    Am J Cardiol; 2015 May; 115(10):1351-6. PubMed ID: 25772742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.
    Gori T; Schulz E; Hink U; Kress M; Weiers N; Weissner M; Jabs A; Wenzel P; Capodanno D; Münzel T
    JACC Cardiovasc Interv; 2015 May; 8(6):770-777. PubMed ID: 25999097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of coronary stent restenosis with drug-eluting bioabsorbable magnesium scaffolds.
    Alfonso F; Cuesta J; García-Guimaraes M; Bastante T; Maruri R; Rivero F
    Coron Artery Dis; 2017 Nov; 28(7):627-628. PubMed ID: 28644215
    [No Abstract]   [Full Text] [Related]  

  • 58. One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
    Shiratori Y; Brugaletta S; Alvarez-Contreras L; Azpeitia Y; Ospino N; Gaido S; Delahanty A; Santos A; Martin-Yuste V; Masotti M; Serruys PW; Windecker S; Sabaté M
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):E428-36. PubMed ID: 23441068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Very late neoatherosclerotic plaque rupture in drug-eluting stent restenosis.
    Courand PY; Dementhon J; Rioufol G; Finet G
    J Cardiovasc Med (Hagerstown); 2015 Jan; 16 Suppl 1():S27-8. PubMed ID: 25333374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optical coherence tomography assessment of in-stent restenosis after percutaneous coronary intervention with two-stent technique in unprotected left main.
    Fujino Y; Attizzani GF; Tahara S; Naganuma T; Takagi K; Yabushita H; Wang W; Warisawa T; Watanabe Y; Mitomo S; Sato T; Kurita N; Ishiguro H; Hozawa K; Nakamura S; Bezerra HG; Nakamura S
    Int J Cardiol; 2016 Sep; 219():285-92. PubMed ID: 27343422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.